Oculis Holding Past Earnings Performance

Past criteria checks 0/6

Oculis Holding's earnings have been declining at an average annual rate of -32.7%, while the Pharmaceuticals industry saw earnings growing at 1.2% annually. Revenues have been declining at an average rate of 5.7% per year.

Key information

-32.7%

Earnings growth rate

30.2%

EPS growth rate

Pharmaceuticals Industry Growth6.0%
Revenue growth rate-5.7%
Return on equity-73.1%
Net Margin-8,020.9%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Oculis: Lack Of Coverage Only Real Risk For This Solid Company

Nov 04

Revenue & Expenses Breakdown

How Oculis Holding makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGM:OCS Revenue, expenses and earnings (CHF Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 241-70210
30 Jun 241-67200
31 Mar 241-59180
31 Dec 231-89170
30 Sep 231-85180
30 Jun 231-78160
31 Mar 231-75130
31 Dec 221-39110
30 Sep 221-3580
31 Dec 211-1950
31 Dec 201-1540

Quality Earnings: OCS is currently unprofitable.

Growing Profit Margin: OCS is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: OCS is unprofitable, and losses have increased over the past 5 years at a rate of 32.7% per year.

Accelerating Growth: Unable to compare OCS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: OCS is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (54.6%).


Return on Equity

High ROE: OCS has a negative Return on Equity (-73.11%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 11:43
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Oculis Holding AG is covered by 8 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Colleen KusyBaird
Jason Matthew GerberryBofA Global Research
Daniil GataulinChardan Capital Markets, LLC